Talazoparib and Thoracic RT for ES-SCLC (NCT04170946)
A Phase I Study of Talazoparib and Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy. Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Cancer Center, University Health Network — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Talazoparib in Combination with Low Dose Radiotherapy (RT) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Princess Margaret Cancer Center, University Health Network — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 946-4501
Email: Benjamin.Lok@rmp.uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.